Lenacapavir sodium

Lenacapavir, also known as GS-6207, is an HIV-1 capsid inhibitor. It demonstrates an average EC50 of 50 pM (ranging from 20-160 pM) against 23 clinical isolates of HIV-1 from diverse subtypes, with tests performed in peripheral blood mononuclear cells (PBMCs) . In vitro, Lenacapavir exhibits picomolar potency and shows no cross-resistance with existing antiretroviral compounds. Furthermore, Lenacapavir displays significant antiviral activity in individuals with HIV-1, regardless of prior treatment history, with no pre-existing resistance detected.

FC(F)(C1=NN(CC(N[C@H](C2=C(C3=C4C(C([N-]S(C)(=O)=O)=NN4CC(F)(F)F)=C(C=C3)Cl)C=CC(C#CC(C)(C)S(C)(=O)=O)=N2)CC5=CC(F)=CC(F)=C5)=O)C6=C1[C@]7([H])[C@@](C(F)6F)([H])C7)F.[Na+]